Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
-
- Toshifumi Tada
- Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan
-
- Takashi Kumada
- Department of Nursing Gifu Kyoritsu University Japan
-
- Atsushi Hiraoka
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
-
- Masashi Hirooka
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan
-
- Kazuya Kariyama
- Department of Gastroenterology Okayama City Hospital Okayama Japan
-
- Joji Tani
- Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan
-
- Masanori Atsukawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
-
- Koichi Takaguchi
- Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan
-
- Ei Itobayashi
- Department of Gastroenterology Asahi General Hospital Asahi Japan
-
- Shinya Fukunishi
- Premier Departmental Research of Medicine Osaka Medical and Pharmaceutical University Osaka Japan
-
- Kunihiko Tsuji
- Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan
-
- Toru Ishikawa
- Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan
-
- Kazuto Tajiri
- Department of Gastroenterology Toyama University Hospital Toyama Japan
-
- Hironori Ochi
- Center for Liver‐Biliary‐Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan
-
- Satoshi Yasuda
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Japan
-
- Hidenori Toyoda
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Japan
-
- Chikara Ogawa
- Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Japan
-
- Takashi Nishimura
- Department of Internal medicine, Division of Gastroenterology and Hepatology Hyogo College of Medicine Nishinomiya Japan
-
- Takeshi Hatanaka
- Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Japan
-
- Satoru Kakizaki
- Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan
-
- Noritomo Shimada
- Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan
-
- Kazuhito Kawata
- Department of Internal Medicine II Hamamatsu University School of Medicine Hamamatsu Japan
-
- Takaaki Tanaka
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
-
- Hideko Ohama
- Premier Departmental Research of Medicine Osaka Medical and Pharmaceutical University Osaka Japan
-
- Kazuhiro Nouso
- Department of Gastroenterology Okayama City Hospital Okayama Japan
-
- Asahiro Morishita
- Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan
-
- Akemi Tsutsui
- Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan
-
- Takuya Nagano
- Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan
-
- Norio Itokawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
-
- Tomomi Okubo
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
-
- Taeang Arai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
-
- Michitaka Imai
- Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan
-
- Atsushi Naganuma
- Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki Japan
-
- Yohei Koizumi
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan
-
- Shinichiro Nakamura
- Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan
-
- Kouji Joko
- Center for Liver‐Biliary‐Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan
-
- Hiroko Iijima
- Department of Internal medicine, Division of Gastroenterology and Hepatology Hyogo College of Medicine Nishinomiya Japan
-
- Yoichi Hiasa
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>The safety and efficacy of atezolizumab plus bevacizumab (Atez/Bev) in elderly patients with unresectable hepatocellular carcinoma (HCC) have not been sufficiently investigated.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 317 patients with HCC treated with Atez/Bev were studied. We compared the survival and frequency of adverse events in elderly versus non‐elderly patients with HCC who were treated with Atez/Bev using an analysis of inverse probability weighting (IPW).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Univariate analysis adjusted with IPW showed that being elderly is not associated with worse overall or progression‐free survival (hazard ratio [HR], 1.239; 95% confidence interval [CI], 0.640–2.399; <jats:italic>p</jats:italic> = 0.526 and HR, 1.256; 95% CI, 0.871–1.811; <jats:italic>p</jats:italic> = 0.223, respectively). Regarding treatment‐related adverse events, any grade of fatigue, proteinuria, decreased appetite, hypertension, and liver injury occurred in ≥10% of patients. There were no significant differences in treatment‐related adverse events between the elderly and non‐elderly groups. In a subgroup analysis of elderly patients aged 75–79, 80–84, or ≥ 85 years, there were no significant differences in cumulative overall or progression‐free survival among these age groups (<jats:italic>p</jats:italic> = 0.960 and 0.566, respectively). In addition, there were no significant differences in treatment‐related adverse events among these three age groups, except for proteinuria of any grade. In a subgroup analysis of patients treated with Atez/Bev as first‐line systemic therapy, there were no significant differences in cumulative overall or progression‐free survival between the elderly and non‐elderly groups (<jats:italic>p</jats:italic> = 0.728 and 0.805, respectively).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Atez/Bev can be used efficaciously and safely in spite of age in patients with unresectable HCC.</jats:p></jats:sec>
Journal
-
- Cancer Medicine
-
Cancer Medicine 11 (20), 3796-3808, 2022-04-19
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360017282217133056
-
- ISSN
- 20457634
-
- Data Source
-
- Crossref
- KAKEN